Sam Brusco, Associate Editor01.18.23
Bausch + Lomb announced that an affiliate of the company has acquired AcuFocus in a merger transaction with AcuFocus’ parent company.
AcuFocus develops small aperture intraocular technology, including the IC-8 Apthera intraocular lens (IOL), approved by the U.S. Food and Drug Administration (FDA) in July 2022 as the first and only small aperture non-toric extended depth of focus (EDOF) IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and also aim to address presbyopia. Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
The IC-8 Apthera IOL features small aperture technology that enables both distance vision correction and near vision correction to mitigate the effects of presbyopia.
“Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15 million individuals, or approximately 45 percent of the more than 33 million cases of global blindness.5 We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb,” Joseph C. Papa, CEO of Bausch + Lomb told the press. “We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better.”
"Bausch + Lomb is a legacy name in eye care with a fully integrated portfolio of offerings in eye health,” added Al Waterhouse, president and CEO, AcuFocus. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
AcuFocus develops small aperture intraocular technology, including the IC-8 Apthera intraocular lens (IOL), approved by the U.S. Food and Drug Administration (FDA) in July 2022 as the first and only small aperture non-toric extended depth of focus (EDOF) IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and also aim to address presbyopia. Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
The IC-8 Apthera IOL features small aperture technology that enables both distance vision correction and near vision correction to mitigate the effects of presbyopia.
“Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15 million individuals, or approximately 45 percent of the more than 33 million cases of global blindness.5 We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb,” Joseph C. Papa, CEO of Bausch + Lomb told the press. “We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better.”
"Bausch + Lomb is a legacy name in eye care with a fully integrated portfolio of offerings in eye health,” added Al Waterhouse, president and CEO, AcuFocus. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
